Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock. D. Boral Capital’s price objective would indicate a potential upside of 455.56% from the stock’s previous close.

HUMA has been the subject of a number of other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Benchmark restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. TD Cowen reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $13.00.

Humacyte Stock Up 0.2 %

Humacyte stock opened at $4.50 on Thursday. The company’s 50-day moving average price is $5.31 and its two-hundred day moving average price is $6.19. The stock has a market cap of $566.37 million, a price-to-earnings ratio of -3.35 and a beta of 1.47. Humacyte has a 52 week low of $2.43 and a 52 week high of $9.97. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insiders Place Their Bets

In other news, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at $10,743,521.28. The trade was a 25.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. This represents a 5.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,584,153 shares of company stock worth $13,476,796. Company insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in Humacyte during the 2nd quarter worth about $28,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Humacyte in the third quarter worth approximately $75,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte during the second quarter worth approximately $83,000. FORA Capital LLC purchased a new position in Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new position in Humacyte in the 2nd quarter valued at approximately $97,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.